Snapshot: August Highlights
A selection of articles you might have missed from August 2022, including a discussion on fake medicines and what's needed to tackle their existence, the die down of SPAC deals and how device-activated drugs may unlock new therapeutic avenues.
You may also be interested in...
An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.
Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.
A selection of articles you may have missed from January 2023, covering the FDA's approach to gene therapies and their long-term implications, the rise (and possible fall) of Chinese companies' efforts in drug development and the ongoing consideration of the 'E' in ESG.